Chapter 99: Antiviral Agents II: Drugs for HIV Infection and Related Opportunistic Infections

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Right now, medical science possesses this pharmacological hack that is just so powerful it can take one of the deadliest viruses in human history and basically render it completely untransmittable.

It really is one of the most dramatic medical advancements we have.

I mean, we are looking at a disease that went from a near certain death sentence to, you know, a manageable chronic condition.

Right.

But that miracle comes at a really steep price.

We're talking about drugs that can cause your liver to fail, give you diabetes, or even trigger a fatal allergic reaction from just a single pill.

Oh, for sure.

The treatment is totally unforgiving.

It requires absolute lifelong adherence.

It costs an absolute fortune.

And it's just this massive minefield of side effects and dangerous drug interactions.

So if you are listening to this right now, chances are you are a nursing student, right?

You're probably prepping for a massive pharmacology exam or maybe getting ready to step onto the floor for clinicals.

And you can't just memorize a list of adverse effects to get by.

You really have to understand the logic behind these medications if you want to keep your patients safe.

Exactly.

So today, your mission, and really our mission, is decoding Chapter 99 of Lens Pharmacology for Nursing Care, the 12th edition.

Yes, the chapter on antiviral agents for HIV and opportunistic infections.

Okay, let's unpack this.

We have to start with the biological battle itself because, I mean, you can't really understand the drugs until you understand the specific enemy they are designed to sabotage.

Right.

So HIV is a retrovirus.

And since we are assuming you already know viruses are obligate intracellular parasites,

let's look at what makes retroviruses so unique.

They carry single -stranded RNA, right?

Not DNA.

Exactly, they carry RNA.

So to replicate, they have to transcribe their RNA backward into DNA.

Hence the retro part of retrovirus.

Yeah, exactly.

And to do that, they use a highly specific viral enzyme called reverse transcriptase.

Okay, and their primary targets in the body are the CD4T cells, which are basically the command centers of the human immune system?

They are.

The virus basically acts like a corporate spy breaking into a highly secure manufacturing plant.

I love that analogy.

So it attaches to the outside of the CD4 cell using these envelope glycoproteins, right?

The GP120 and GP41.

Right.

It docks at the CD4 receptor, but it can't just walk in.

It also needs a co -receptor, which is usually CCR5 or CXCR4, to actually pull off the break -in.

Okay.

So once it fuses and gets inside, that reverse transcriptase enzyme goes to work.

It's basically stealing the plant's blueprints, turning its viral RNA into double -stranded DNA.

Yep.

And then a second enzyme called integrase comes into play.

It inserts that viral code directly into the host cell's DNA.

Oh, wow.

So at that point, the mainframe is totally hacked.

Completely hacked.

The cell is effectively permanently infected at that point.

The plant's machinery just starts manufacturing millions of clone viruses.

And then there's a third enzyme, right?

Protease.

Right.

Protease.

It acts like a quality control inspector.

It cleaves these long, non -functional polyproteins into mature infectious viruses.

And then those clones butt off, and they end up killing the CD4 cell on their way out.

They do.

But the virus doesn't just destroy CD4 cells.

It also infects macrophages and microglial cells in the central nervous system.

Wait.

Do those cells die, too?

Actually no.

Those cells don't die.

They become a viral reservoir, which means they harbor the virus during chronic infection.

Ah, so it just hides out there.

Exactly.

And this reservoir is the main reason we can't completely cure HIV right now.

That makes sense.

So if we look at the clinical course of the disease, this infection comes in three phases.

Right.

The initial phase is this massive explosion of viral replication.

You're talking about over 10 million virions per milliliter of blood.

Which is when patients get that flu -like acute retroviral syndrome, right?

The one that is just incredibly easy to miss because it looks like a normal flu.

Exactly.

And then comes the clinical latency phase, which didn't actually last a decade.

The virus is still replicating, but the blood levels are much lower.

And then finally the late phase, which is AIDS.

That hits when CD4 counts drop below 200, leaving the patient totally vulnerable.

Right.

And something you have to understand is that during that steady middle latency phase, the virus is replicating at a staggering rate,

like 1 to 10 billion virions a day.

Billions every day.

Every single day.

Furthermore, reverse transcriptase is a notoriously sloppy enzyme.

It makes constant transcription errors.

Meaning the virus mutates rapidly.

Wait, so if it's mutating constantly and making billions of copies a day, how can giving a patient one drug possibly stop it?

Well, it can't.

It would just mutate around that drug in a week.

Oh wow.

So you just lose the drug entirely.

Exactly.

Which is exactly the problem.

And it basically dictates all of modern HIV pharmacology.

Monotherapy is never used.

Because the resistance develops almost immediately.

Right.

You must attack it from multiple angles at once using combination therapy.

Okay.

But because we are using combination therapy, we immediately step into a major nursing safety alert from the text.

The cytochrome P450 minefield.

Yes.

This is crucial.

Many antiretroviral drugs are heavily metabolized by CYP450 enzymes in the liver.

And it's not just that they're metabolized by them, right?

They frequently act as inducers or inhibitors of these exact same enzymes.

Exactly.

So if you're looking at a test question and you see one of these drugs paired with another medication,

your immediate instinct should be to look for metabolic interactions.

Right.

So if a drug is an inducer, I picture it like a traffic cop waving cars through an intersection at top speed.

That's a great way to look at it.

The liver speeds up metabolism.

So it clears drugs out of the patient's body before they can even work.

Which risks total treatment failure.

Conversely, if a drug is an inhibitor, it puts up roadblocks.

Metabolism slows down.

So you get this massive toxic traffic jam of drugs just accumulating in the bloodstream.

Exactly.

And it's not just metabolic interactions you have to watch out for.

You also have shared adverse effects.

Additive effects, right.

Like, if you give two different drugs that both cause bone marrow suppression, the patient's immune system takes double the hit.

Exactly.

Throw in common comorbidities for advanced HIV patients like hepatitis C or tuberculosis, and the interaction risk just skyrockets.

Okay.

So let me push back here.

As a nursing student, do I just sit down with a stack of flashcards and memorize every single bad combination?

Honestly, no.

The interaction lists are simply too long and they are constantly changing.

So what do you do in practice?

Any nurse administering these drugs relies on up -to -date drug interaction software that is capable of checking multiple drugs simultaneously.

Okay, that is a relief.

But listen, your job isn't to memorize the database.

Your job is to understand the underlying physiological why when that software throws a red flag.

You have to know what the red flag actually means.

Okay, let's get into the actual toolkit of drugs.

Let's do it.

We know the virus uses reverse transcriptase to turn its RNA into DNA.

So let's start with the first two classes of drugs that target that exact enzyme.

First up, the NRTIs.

Right, the nucleoside and nucleotide reverse transcriptase inhibitors.

These are actually the oldest class of HIV drugs.

And the text uses abacavir as a standard prototype here.

Yes.

Now these are pro -drugs, meaning they have to be converted into their active form inside the cell.

Okay, and once they're active, they act as faulty building blocks for the viral DNA.

I always picture this like building a tower out of Lego bricks.

Okay, I like where this is going.

So the reverse transcriptase enzyme is grabbing nucleotides and stacking them to build the DNA chain.

The NRTI is like handing it a faulty Lego brick.

The enzyme grabs it, sticks it onto the chain, and… And because it lacks the necessary chemical hook, nothing else can attach to it.

Oh, so it just ends there.

Exactly.

It causes premature strand termination.

The entire assembly line just grinds to a halt.

That is brilliant.

But this entire class carries a black box warning, right, for fatal lactic acidosis and hepatomegaly with steatosis, which is basically a severe fatty liver.

They do.

It's a serious risk.

But why?

Like why does a faulty viral DNA building block destroy the patient's liver and spike their lactic acid?

Because occasionally those faulty building blocks trick the patient's own cellular machinery, specifically the DNA polymerase inside the patient's mitochondria.

Oh wow.

So the NRTIs are inhibiting human mitochondrial replication too.

Exactly.

Leading to mitochondrial toxicity.

Without healthy mitochondria, the cells can't process energy normally.

Which leads to a buildup of lactic acid and the fatty degeneration of the liver.

So as a nurse, you have to monitor for early signs of toxicity like nausea, fatigue, and hyperventilation.

Right.

And for our prototype, ABACAVER, there is an absolute prerequisite you have to know for exams.

It's genetic screening for the HLA -B5701 variation.

HLA -B5701, okay.

What happens if they have it?

If a patient tests positive for that specific genetic marker, they have an extraordinarily high risk of developing a fatal hypersensitivity reaction to ABACAVER.

Like multi -organ failure and anaphylaxis.

Exactly.

So if they test positive, they can never ever take it.

It's an absolute contraindication.

Okay.

So a few other NRTIs to keep on your radar for clinicals or exams.

There's Zetovudine, which was actually the very first HIV drug.

And it's notorious for severe bone marrow suppression.

You have to monitor hemoglobin.

Neutrophil counts religiously with that one.

Got it.

Then there's antricidabine, which has a weird, very specific side effect of hyperpigmentation on the palms and soles of the feet.

Right.

Okay.

So moving to the second class that targets this enzyme,

the NNRTIs, or non -nucleoside reverse transcriptase inhibitors.

And efavirenz is the preferred first -line prototype here.

So if the NRTIs are faulty Lego bricks, how do the NNRTIs work?

They are more like pouring superglue onto the Lego builder's hands.

Oh, I like that.

So they aren't building blocks at all.

No, they don't pretend to be building blocks.

They bind directly to the active center of the reverse transcriptase enzyme itself, crippling its ability to function.

So the enzyme just can't do anything.

But efavirenz brings a whole different set of dangers.

It frequently causes a rash that you have to watch like a hawk.

Yes, because that rash can progress to Stevens -Johnson syndrome, where the top layer of skin basically dies and sheds.

It's a medical emergency.

And it's also teratogenic, right?

Patients of childbearing potential need two forms of birth control, a barrier method plus a hormonal method.

Right.

And the two forms are required because efavirenz actually induces the CYP450 enzymes that metabolize hormonal contraceptives.

Ah, so it makes the birth control pill less effective.

That is a critical piece of patient education.

It also hits the central nervous system pretty hard, doesn't it?

It does.

Dizziness, insomnia, impaired concentration, even hallucinations.

OK, wait.

If it makes patients feel that terrible and gives them hallucinations, how do we get them to stick to a lifelong daily regimen?

You use a highly specific nursing intervention.

You teach the patient to take the medication on an empty stomach right at bedtime.

Oh, so they sleep through it.

Exactly.

The goal is for them to sleep through the peak blood levels and bypass the absolute worst of those CNS effects.

That is so smart.

OK, so we've tried to sabotage the blueprints, but viruses are resilient.

What if the virus manages to build its DNA anyway?

Then we move further down the biological assembly line.

We have two more viral enzymes to target,

integrase and protease.

Let's start with integrase.

The integrase strand transfer inhibitors, or NSTIs.

Rolta -Graver is the prototype here, right?

Right.

Remember that integrase is the enzyme that inserts the viral DNA into the host cell's DNA.

Rolta -Graver blocks this exact step.

So it stops the hostile takeover of the mainframe.

But wait, the virus is still inside the cell at this point.

It is, but without integrating its DNA, the virus can't hijack the cell to produce new variants.

The cell is infected, but the replication cycle is completely broken.

OK, that makes sense.

And how are the side effects for NSTIs?

They are actually generally very well tolerated.

You'll mostly see some insomnia and headache, though, as always, keep an eye out for rare hypersensitivity reactions.

Good to know.

Which brings us to the last enzyme,

protease.

The protease inhibitors, or PIs.

And the prototype here is darunavir.

Right.

Protease is that quality control inspector we talked about.

It cleaves the large, clunky polyproteins into small, functional pieces so the new virus can mature.

So if you block protease with darunavir?

The newly formed virus particles still bud off from the host cell, but they are completely immature and non -infectious.

They literally cannot infect other CD4 cells.

Wow.

But I remember the text saying PIs come with an immense metabolic burden.

Huge.

We are talking about hyperglycemia and new onset diabetes.

Men, fat redistribution, right, causing this Cushingord appearance, like, truncal obesity and a fat pad on the back of the neck, often called a buffalo hump.

Yes.

Plus hyperlipidemia and significant bone loss.

Why does an antiviral drug cause a patient to develop diabetes and lose bone density?

That seems so unrelated.

Well, protease inhibitors interfere with cellular mechanisms beyond just the virus.

They induce insulin resistance, meaning the patient's human cells stop responding to insulin, which drives up blood sugar.

Okay.

And the fat?

They alter lipid metabolism, causing the fat redistribution and hyperlipidemia, and they interfere with osteoplast function.

Which prevents new bone formation.

That is a massive toll on the body.

Oh, and didn't the books say they can also prolong the PR interval on an EKG messing with cardiac conduction?

They do.

It's a lot for a patient to handle.

But this is also where we see that mind -blowing pharmacological hack we hinted at earlier.

Oh, right.

The ratonavir boosting.

So you'll almost always see darunavir prescribed alongside another PI called ratonavir.

But the ratonavir is given at this tiny dose.

Right.

Because ratonavir is a potent inhibitor of CYP3A4 enzymes in the liver.

Wait.

So we are taking a drug's dangerous side effect, its ability to cause a massive metabolic roadblock, and we are weaponizing it on purpose.

We are.

We cause a localized CYP450 traffic jam just to boost the blood levels of the primary drug, the darunavir.

That is exactly the strategy.

The ratonavir dose is way too low to fight the virus effectively on its own, but it perfectly blocks the liver from breaking down the darunavir.

Which keeps the darunavir levels high and effective with less frequent dosing.

That is genius.

It is, but if I'm a nurse, my alarm bells should be ringing.

Oh, because if ratonavir is shutting down liver metabolism, that intentional traffic jam is going to affect almost any other medication the patient is taking.

Exactly.

Which requires extreme vigilance.

You have to cross -reference every single medication, supplement, or over -the -counter drug the patient takes.

You cannot afford to miss anything.

Absolutely.

Okay, so far, we've spent this whole deep dive trying to sabotage the virus once it's already inside the factory, but there's a completely different strategy, right?

Yes.

What if we just change the locks on the doors so the virus can't get in at all?

The entry inhibitors?

Exactly.

There are four types, starting with the fusion inhibitors.

The prototype is infuvertide.

And it basically binds to the viral envelope and physically prevents it from fusing with the CD4 cell membrane.

Right, but the drawback is astronomical.

It requires subcutaneous injections twice a day, costs around $52 ,000 a year, and nearly 100 % of patients get painful injection site reactions.

Okay, I have to push back here.

If we have relatively easy oral pills like the NRTIs and the NSTIs, why on earth would any prescriber put a patient on a $52 ,000 drug that requires painful daily injections?

What is the clinical utility?

That's a great question.

You only pull out these entry blockers when your back is against the wall.

So it's a last resort?

Yeah, they are the heavy artillery reserves specifically for patients with multi -drug resistant HIV strains where standard oral therapies have completely failed.

So when the virus is actively destroying the immune system again, you use this as salvage therapy.

Exactly.

Another lock changer is Mariviroc, which is a CCR5 antagonist.

It binds to the CCR5 co -receptor on the outside of the CD4 cell.

But as a nurse, you can't just hand this to a patient.

There's a mandatory prerequisite test here, too.

Right.

Remember how we said HIV uses CCR5 or CXCR4 to enter the cell?

Not all HIV strains use CCR5.

Some use CXCR4 or both.

Right.

So before you ever administer Mariviroc, the patient must undergo a tropism assay.

It's a specialized blood test to prove their specific strain of HIV actually uses the CCR5 receptor.

Because if it doesn't, the drug is completely useless.

The virus will just use the other door.

And you also have to monitor closely for hepatotoxicity with that one, right?

You do.

And just to write out the class, there were two newer entry blockers for multidrug -resistant HIV.

Fostum Savior, an attachment inhibitor that binds to the virus's GP120 spikes.

And Ibalzumab, a post -attachment inhibitor.

Interestingly, Ibalzumab is an IV monoclonal antibody that binds directly to Domain 2 of the CD4 receptor on the human cell itself.

Right.

So we now have the complete pharmacology toolkit.

We block entry, reverse transcription, integration, and maturation.

So we've got the tools, but what does this all mean for the patient sitting in front of you?

Like, how do you actually manage this care as a nurse?

It all comes down to monitoring the labs and managing the whole patient.

The two most critical lab tests are the CD4 T -cell count and the plasma HIV RNA, which is the viral load.

If you are taking an exam, you have to keep these straight.

The CD4 count tells you how much damage the immune system has already taken.

Right.

It's your principal indicator of immune competence.

It tells you when you need to start or stop prophylactic antibiotics.

And the viral load, on the other hand, tells you how well your drug therapy is actively suppressing the virus right now.

Exactly.

The therapeutic goal of antiretroviral therapy, or ART, is to reduce the viral load to completely undetectable levels.

Which is what allows the CD4 count to eventually recover.

And current treatment guidelines require at least three drugs from two different classes, right?

Always.

And ART is recommended for everyone with HIV, including all pregnant patients, to prevent perinatal transmission to the baby.

We also use these drugs prophylactically, don't we?

Like pre -EP or exposure prophylaxis for people at high risk of contracting HIV.

Yes.

And PP, post -exposure prophylaxis, which is a 28 -day course of meds you take if you've had an accidental exposure.

Like a needle stick during a clinical rotation.

Exactly.

But the scientific data highlights an incredible paradox in modern HIV care that is so important for patient teaching.

The U equals U thing.

Research conclusively shows that patients who maintain an undetectable viral load for six months or more do not transmit HIV to sexual partners.

U equals U.

Undetectable equals untransmittable.

Wow.

That is a massing breakthrough for reducing the stigma around the disease.

It is huge.

But the paradox is that these drugs don't cure the virus.

Those macrophages we talked about earlier are still acting as a dormant reservoir.

So if the patient misses doses or, like, stops taking their pills because of side effects, the virus rebounds from those reservoirs almost immediately.

Which is exactly why the burden of adherence is so astronomical.

If adherence fails, or the patient loses access to their care, the viral load spikes and the CD4 count plummets.

And when that CD4 count drops below 200, the patient enters the late phase, AIDS.

Right.

This profound immunosuppression basically opens the door for opportunistic infections.

These are infections by organisms that rarely cause disease in a healthy immune system.

But without CD4 cells to coordinate the defense, the body is totally defenseless.

A major one is Pneumocystis Pneumonia, or PCP.

Right.

And PCP is technically a fungal infection of the lungs, but uniquely the treatment of choice is actually an antibacterial combination, trimethoprim sulfamethoxazole.

Also known as Bactrim.

You also see cytomegalovirus, or CMV retinitis.

The virus attacks the retina and can actually cause permanent blindness.

And candidiasis, right, oral thrush, which coats the mouth and throat in these painful white plaques.

That's treated topically with myconazole, or systemically with fluconazole.

Exactly.

Preventing those infections is why the nurse's role is so immense here.

You aren't just passing meds, you are the ultimate educator and support system.

You are tracking bone density, monitoring blood sugar for new onset diabetes, checking for liver toxicity and those Stevens -Johnson rashes.

And finding ways to keep the patient motivated when pill fatigue inevitably sets in.

It's holistic care in the truest sense.

So to wrap up our deep dive,

we've traced the biological battle from the microscopic break -in of a CD4 cell to the clever ways we use faulty building blocks and enzyme superglue to stop viral replication.

We look at how we weaponize CYP450 traffic jams and the absolute vigilance required to manage the side effects and prevent opportunistic infections.

Right.

So do you have a final thought to leave the listeners with?

I do.

Something to ponder as you study.

Because these medications are so effective, patients with HIV are now living into their 70s and 80s.

Which is incredible.

It is a profound medical triumph.

But it means the next great frontier in nursing won't just be managing the virus itself.

It will be managing the decades of cumulative metabolic side effects.

Oh wow.

The diabetes.

The severe osteoporosis.

The hyperlipidemia.

Exactly.

The issues caused by the very drugs keeping these patients alive.

That's the future of this care.

That is a wild thing to think about.

The tools we have now are giving people their entire lives back.

It just requires us to be sharp, to understand the why behind the meds, and to care for the whole person.

Absolutely.

Well, good luck on your exams and good luck in clinicals.

A warm thank you from the Last Minute Lecture Team for diving in with us.

Keep studying and we'll see you next time.